Compare OPLN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPLN | ICUI |
|---|---|---|
| Founded | 2006 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.6B |
| IPO Year | N/A | 1992 |
| Metric | OPLN | ICUI |
|---|---|---|
| Price | $30.15 | $156.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $28.00 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 796.1K | 217.4K |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 357.93 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | $1,895,200,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | $8.75 | N/A |
| Revenue Next Year | $5.09 | N/A |
| P/E Ratio | $34.59 | ★ N/A |
| Revenue Growth | ★ 6.75 | N/A |
| 52 Week Low | $17.08 | $107.00 |
| 52 Week High | $31.78 | $175.51 |
| Indicator | OPLN | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 66.21 |
| Support Level | N/A | $146.33 |
| Resistance Level | N/A | $152.97 |
| Average True Range (ATR) | 0.00 | 5.14 |
| MACD | 0.00 | 0.54 |
| Stochastic Oscillator | 0.00 | 95.19 |
Openlane Inc provides a digital marketplace for used vehicles, connecting sellers and buyers in North America and Europe for fast and transparent transactions. Its services include financing, repossessions, repairs, transportation, warranty, and inventory management. The company operates used-vehicle auctions and has two main segments: Marketplace and Finance, with majority revenue coming from the Marketplace segment, which to used vehicle remarketing, including marketplace services, remarketing, or make ready services and all are interrelated, synergistic elements along the auto remarketing chain. The Finance segment, through AFC engaged in business of providing short-term, inventory-secured financing to independent vehicle dealers.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.